Ondansetron, Dexamethasone
Phase 3Small molecule
Ondansetron, Dexamethasone is one of 94 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
93
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
84 competitors in Cesarean Section
#DrugCompanyPhaseTrials
1Fentanyl-Morphine
SSeoul National University Hospital
Phase 3
Ondansetron, Dexamethasone
KKing Khaled Eye Specialist Hospital
Phase 3
Acetaminophen/ibuprofen
SSeoul National University Hospital
Phase 3
Morphine - .
RRambam Health Care Campus
Phase 3
Sebacoyl Dinalbuphine Ester
LLumosa Therapeutics Co., Ltd.
Phase 3
Proamatine
TakedaPreclinical
Dynastat
PfizerPreclinical
Duragesic
CCephalon
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Catapres
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dexamethasone1 trial
Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
Completed·—·Phase 4·NCT00734929·115 enrolled
Cesarean Section1 trial
Role of Prophylactic Antiemetics in Women Receiving Intrathecal Morphine and Lipophilic Opioids Added to Bupivacaine for Cesarean Section
Not yet recruiting·—·Phase 4·NCT06704139·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ondansetron, Dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details